AstraZeneca, citing a study, said its COVID-19 vaccine is effective against Delta and Kappa variants, which were first identified in India, as reported by U.S. News & World Report.
The University of Oxford study investigated the ability of monoclonal antibodies in blood from recovered people and from those vaccinated to neutralize the variants.
An analysis by Public Health England (PHE) last week showed that vaccines developed by Pfizer and AstraZeneca offer protection of more than 90% against hospitalization from the Delta variant.
AstraZeneca said the latest results are built on the recent analysis by PHE.
To read more NewsPoints articles, click here.